Amenorrhea, Anovulatory Bleeding, and PCOS Pharmacotherapy
Core concept: Amenorrhea and anovulatory bleeding are clinical presentations with different etiologies; drug treatment is directed at the cause, endometrial safety, symptom burden, and reproductive goals.
Key clinical distinction: Anovulatory bleeding associated with PCOS is not treated the same way as hypothalamic amenorrhea, hyperprolactinemia, thyroid disease, or primary ovarian insufficiency.
Prescribing priority: Exclude pregnancy, evaluate etiology, and determine whether the patient’s immediate goal is cycle regulation, endometrial protection, metabolic health, or conception (Cieri-Hutcherson, 2026).
Initial clinical evaluation
Characterize prior cycle regularity, duration of amenorrhea, weight or exercise changes, stress, medications, galactorrhea, headaches or visual symptoms, hot flashes, acne, hirsutism, pregnancy risk, and fertility goals. Pregnancy testing is an early step when pregnancy is biologically possible. Evaluate TSH, prolactin, gonadotropins, estradiol, androgen parameters, and metabolic markers when indicated rather than ordering a fixed panel without regard to the presentation. Assess for structural or other disease when bleeding is substantial or atypical. Avoid assuming that every irregular cycle is PCOS (Cieri-Hutcherson, 2026).
PCOS: cycle regulation and endometrial protection
For a patient not seeking pregnancy, combined hormonal contraception can control bleeding and improve some androgen-related symptoms when estrogen is eligible. If estrogen is unsuitable, periodic oral progestogen or a levonorgestrel IUD can provide endometrial protection and help manage bleeding patterns. Cyclic medroxyprogesterone acetate is one option for endometrial protection, but dose and schedule should be matched to the indication and bleeding pattern. A patient with prolonged anovulation needs protection against unopposed estrogen’s endometrial effects even if the irregular bleeding is not bothersome (Cieri-Hutcherson, 2026).
Metabolic treatment and fertility goals
Metformin can address insulin resistance and selected metabolic features of PCOS, but is not automatically superior to hormonal treatment for cycle control. Representative dosing is approximately 1,500–2,000 mg daily in divided doses for selected patients, titrated to GI tolerance and kidney function. Return of ovulation may occur even without predictable periods, so address contraception when pregnancy is not desired. For PCOS-related infertility, ovulation-induction options such as letrozole and clomiphene require preconception evaluation and a coordinated fertility plan, often with specialist oversight (Cieri-Hutcherson, 2026).
Other etiologies change therapy
Hyperprolactinemia may call for a dopamine agonist such as cabergoline after confirming the diagnosis and assessing pituitary causes. Functional hypothalamic amenorrhea requires correction of energy imbalance and underlying causes, not a contraceptive alone as a substitute for recovery. Thyroid disease requires thyroid-specific management; primary ovarian insufficiency calls for distinct counseling about hormone support and fertility. A medication-induced prolactin rise should prompt medication reconciliation before reflexive addition of another medication (Cieri-Hutcherson, 2026).
Monitoring and treatment response
Monitor bleeding pattern, anemia when relevant, metabolic parameters, blood pressure, medication effects, patient goals, and endometrial protection. Anovulatory bleeding with sustained amenorrhea, intermenstrual bleeding, significant blood loss, or risk factors for hyperplasia may require gynecologic evaluation and tissue assessment. Do not promise that oral contraceptives treat the underlying cause of every amenorrhea presentation (Cieri-Hutcherson, 2026).
Separate endometrial protection from metabolic and fertility treatment
Anovulatory bleeding in PCOS requires attention to prolonged unopposed estrogen exposure and endometrial protection. For patients not seeking pregnancy, eligible combined hormonal contraception can regularize cycles and help acne, while cyclic progestogen or an LNG-IUD may provide endometrial protection when estrogen is unsuitable. Metformin may address dysglycemia and selected metabolic concerns but is not an interchangeable treatment for hirsutism, contraception, or immediate infertility. Patients seeking pregnancy need a different pathway that may include specialist-directed letrozole rather than contraceptive cycle control (Cieri-Hutcherson, 2026).
Use objective response and exclusion testing
Exclude pregnancy first, then assess thyroid and prolactin disorders, premature ovarian insufficiency, medication-related causes, and hypothalamic suppression when indicated. Measure BP, metabolic markers, menstrual frequency, bleeding severity, and treatment tolerance. Reassess if prolonged amenorrhea persists, bleeding becomes heavy, or new androgen-excess red flags develop. The treatment plan should specify an endometrial-protection strategy and a documented plan if the patient switches from pregnancy avoidance to conception (Cieri-Hutcherson, 2026).
Clinical application
A 28-year-old with PCOS, oligomenorrhea, elevated A1c, and acne wants pregnancy prevention for 18 months. Compare an eligible combined contraceptive, which can address cycles/acne and protect the endometrium, with an LNG-IUD plus separate acne/metabolic therapy. Metformin may be useful for dysglycemia but is not stand-alone endometrial protection or reliable contraception. If she returns wanting pregnancy, discontinue the contraceptive pathway and initiate infertility/preconception evaluation and specialist-directed induction planning (Cieri-Hutcherson, 2026).
High-yield distinctions
Pregnancy must be considered first. Anovulatory bleeding can indicate prolonged endometrial estrogen exposure. Metformin is not contraception and may increase ovulation. Treat the underlying cause of amenorrhea rather than the calendar alone.
Related YourDNP Resources
Pharmacology learning hub · Combined hormonal contraception · Heavy menstrual bleeding · Ovulation-induction pharmacology · Menopausal hormone therapy
Content last reviewed:
References
Cieri-Hutcherson, N. E. (2026). Menstruation-related disorders and menopause. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 50). McGraw Hill.
Vernon, V. P. (2026). Contraception. In M. A. Chisholm-Burns, P. M. Malone, J. M. Kolesar, K. C. Lee, P. B. Bookstaver, & K. R. Matthias (Eds.), Pharmacotherapy principles & practice (7th ed., Chapter 49). McGraw Hill.